Defense against hypoglycemia is critical for survival, and is of particular importance in the clinically-significant setting of insulin-induced hypoglycemia. Insulin-induced hypoglycemia is prevalent in Type 1 and advanced Type 2 diabetes mellitus, and is associated with a far-ranging negative impact, including reduced work productivity and quality of life, decreased adherence to or recommendations for intensive insulin regimens (resulting in poorer glycemic control), increased incidence of hypoglycemia-related morbidity and unfortunately, occasionally death. Several facets of ghrelin biology suggest that the ghrelin system may participate in the counter-regulatory response to insulin-induced hypoglycemia: Ghrelin secretion is directly stimulated by low glucose. The ensuing raised ghrelin has at its disposal many potential downstream targets with which to influence glucose handling, including stimulation of food intake, reduction of insulin secretion and insulin sensitivity, and enhancement of hepatic gluconeogenesis and hepatic autophagy. Also, the ghrelin system directly interacts with several arms of the traditional counter-regulatory response to hypoglycemia, including stimulation by ghrelin of glucagon and GH secretion, elevation by ghrelin of circulating glucocorticoids and induction of ghrelin release by increased sympathetic nervous system activity. Thus, ghrelin is well-positioned to play a central protective glucoregulatory role during insulin-induced hypoglycemia. However, while ghrelin regulation of blood glucose and by blood glucose have been evaluated in some contexts (e.g. fasting, postprandial, etc.), the overall role of the ghrelin system in the counter-regulatory response to insulin-induced hypoglycemia has not been fully assessed experimentally, for instance by re-creating insulin-induced hypoglycemia in mice without an intact ghrelin system. Here, we will test the concept that ghrelin plays a key, protective, counter-regulatory role in the body's response to insulin-induced hypoglycemia. We will accomplish this by studying effects of insulin-induced hypoglycemia on both ghrelin action and ghrelin secretion using a unique collection of recombinant mouse models. These models include ghrelin-knockout mice and three novel lines: mice lacking insulin receptors exclusively from ghrelin cells, mice lacking GHSRs exclusively from preproglucagon cells, and mice with preproglucagon cell-selective expression of GHSRs on an otherwise GHSR-null background. We will emulate insulin-induced hypoglycemia in these mouse models of altered ghrelin action and secretion using 2 ?gold-standard? paradigms for assessing the counter-regulatory response: insulin-induced (hyperinsulinemic)-hypoglycemic clamp and an insulin bolus-induced hypoglycemia protocol, neither of which have been reported before in mice with altered ghrelin systems. Together with these novel mouse models, our team's experience in studying both ghrelin action and secretion and our expertise with clamp technology and glucose metabolism in mice uniquely position us to address important questions regarding the impact of the ghrelin system on the counterregulatory response to insulin-induced hypoglycemia.

Public Health Relevance

Defense against hypoglycemia is critical for survival, and is of particular importance in the clinically-significant and prevalent setting of insulin-induced hypoglycemia that occurs in Type 1 and advanced Type 2 diabetes mellitus. The experiments proposed in this grant application will establish the role of the peptide hormone ghrelin in the body's counter-regulatory response to insulin-induced hypoglycemia, as is hypothesized based on work demonstrating blood glucose-raising actions for ghrelin and sensing of hypoglycemia signals by ghrelin cells. Advancing our understanding of the coordinated counter-regulatory response to insulin-induced hypoglycemia might permit the development of new treatment modalities for diabetes that will provide improved glucose control with the added benefit of reduced hypoglycemia and hypoglycemia-related morbidity and mortality.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56DK071320-09A1
Application #
9275118
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Teff, Karen L
Project Start
2005-03-01
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
9
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Gautron, L; Cravo, R M; Elmquist, J K et al. (2013) Discrete melanocortin-sensitive neuroanatomical pathway linking the ventral premmamillary nucleus to the paraventricular hypothalamus. Neuroscience 240:70-82
Rossi, Jari; Balthasar, Nina; Olson, David et al. (2011) Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab 13:195-204
Gautron, Laurent; Lee, Charlotte; Funahashi, Hisayuki et al. (2010) Melanocortin-4 receptor expression in a vago-vagal circuitry involved in postprandial functions. J Comp Neurol 518:6-24
Williams, Kevin W; Scott, Michael M; Elmquist, Joel K (2009) From observation to experimentation: leptin action in the mediobasal hypothalamus. Am J Clin Nutr 89:985S-990S